^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    crenolanib (ARO-002)

    i
    Company:
    AROG
    Drug class:
    FLT3 inhibitor, PDGFR α inhibitor, PDGFR β inhibitor
    Related drugs:
    Apply
    Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients (NCT02400281)
    Phase 1/2
    Arog Pharmaceuticals, Inc.
    Completed
    Last update posted :
    03/20/2024
    Initiation :
    09/01/2015
    Primary completion :
    07/15/2020
    Completion :
    07/15/2020
    FLT3
    |
    FLT3 mutation
    |
    cytarabine • azacitidine • etoposide IV • crenolanib (ARO-002) • idarubicin hydrochloride • mitoxantrone • fludarabine IV
    A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations (NCT02283177)
    Phase 2
    Arog Pharmaceuticals, Inc.
    Completed
    Last update posted :
    02/02/2024
    Initiation :
    01/01/2015
    Primary completion :
    12/01/2019
    Completion :
    12/01/2019
    FLT3
    |
    FLT3-ITD mutation
    |
    cytarabine • crenolanib (ARO-002) • daunorubicin • idarubicin hydrochloride
    Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations (NCT01522469)
    Phase 2
    Arog Pharmaceuticals, Inc.
    Completed
    Last update posted :
    01/30/2024
    Initiation :
    07/01/2012
    Primary completion :
    08/01/2014
    Completion :
    11/01/2014
    FLT3
    |
    FLT3-ITD mutation
    |
    crenolanib (ARO-002)
    Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients (NCT02400255)
    Phase 2
    Arog Pharmaceuticals, Inc.
    Completed
    Last update posted :
    12/18/2023
    Initiation :
    09/01/2015
    Primary completion :
    05/01/2022
    Completion :
    05/01/2022
    HLA-DRB1
    |
    FLT3 D835
    |
    crenolanib (ARO-002)
    A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations (NCT01657682)
    Phase 2
    Arog Pharmaceuticals, Inc.
    Completed
    Last update posted :
    11/30/2023
    Initiation :
    10/01/2012
    Primary completion :
    04/01/2019
    Completion :
    04/01/2019
    FLT3
    |
    FLT3-ITD mutation
    |
    crenolanib (ARO-002) • hydroxyurea
    Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML (NCT03250338)
    Phase 3
    Arog Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    04/30/2021
    Initiation :
    06/05/2018
    Primary completion :
    10/01/2024
    Completion :
    10/01/2024
    FLT3
    |
    FLT3-ITD mutation • FLT3 D835
    |
    cytarabine • crenolanib (ARO-002) • idarubicin hydrochloride • mitoxantrone
    Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST (NCT02847429)
    Phase 3
    Arog Pharmaceuticals, Inc.
    Active, not recruiting
    Last update posted :
    01/22/2021
    Initiation :
    08/01/2016
    Primary completion :
    08/01/2021
    Completion :
    08/01/2021
    PDGFRA
    |
    PDGFRA D842V • PDGFRA mutation
    |
    crenolanib (ARO-002)
    Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification (NCT02626364)
    Phase 2
    Arog Pharmaceuticals, Inc.
    Completed
    Last update posted :
    07/20/2020
    Initiation :
    04/01/2016
    Primary completion :
    07/01/2020
    Completion :
    07/01/2020
    PDGFRA
    |
    crenolanib (ARO-002)
    Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML (NCT03258931)
    Phase 3
    Arog Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    05/22/2020
    Initiation :
    08/15/2018
    Primary completion :
    11/01/2022
    Completion :
    11/01/2024
    FLT3
    |
    FLT3-ITD mutation
    |
    cytarabine • midostaurin • crenolanib (ARO-002)
    A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia (NCT03324243)
    Phase 2
    Arog Pharmaceuticals, Inc.
    Withdrawn
    Last update posted :
    01/10/2019
    Initiation :
    01/01/2018
    Primary completion :
    12/01/2020
    Completion :
    12/01/2020
    FLT3
    |
    FLT3-ITD mutation • FLT3 D835 • FLT3 I836
    |
    cytarabine • crenolanib (ARO-002) • fludarabine IV
    Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene (NCT01243346)
    Phase 2
    Arog Pharmaceuticals, Inc.
    Completed
    Last update posted :
    06/28/2018
    Initiation :
    04/01/2011
    Primary completion :
    07/01/2014
    Completion :
    07/01/2014
    PDGFRA
    |
    PDGFRA D842V • PDGFRA mutation
    |
    crenolanib (ARO-002)
    Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (NCT02270788)
    Phase 1
    St. Jude Children's Research Hospital
    Completed
    Last update posted :
    10/03/2017
    Initiation :
    04/02/2015
    Primary completion :
    10/17/2016
    Completion :
    10/17/2016
    FLT3 • MPO
    |
    sorafenib • cytarabine • crenolanib (ARO-002) • leucovorin calcium